CPAP therapy, the traditional standard for obstructive sleep apnea (OSA), is universally despised by patients, resulting in abysmally low compliance rates. Recent studies show it also fails to effectively reduce cardiovascular risks. Vivos Therapeutics offers a highly effective alternative with easy, comfortable treatment that takes just months, yielding results that can last a lifetime.
LITTLETON, Colo., Jan. 29, 2025 /PRNewswire-PRWeb/ -- Obstructive Sleep Apnea (OSA) affects over 1 billion adults and children in worldwide, including an estimated 90 million people in the United States alone. (1-3) While continuous positive airway pressure (CPAP) therapy has long been regarded as the standard front-line treatment, its widespread use hides a troubling reality: compliance rates remain alarmingly low. "Recent unpublished data from 100,000 OSA patients over 15 years, suggests that as few as 12% of CPAP users remain consistently active in treatment over extended periods of time," says Kirk Huntsman, Chairman and CEO of Vivos Therapeutics, a leading innovator in medical technology dedicated to improving breathing and sleep health. "We need to move beyond the outdated paradigm of CPAP as the primary treatment, which merely manages the disease, and instead embrace innovative approaches aimed at eradicating it altogether."
The Compliance Crisis: CPAP's Limitations
CPAP adherence rates vary significantly across demographics, with women aged 18 to 30 demonstrating the lowest adherence rates. (4) Common patient complaints include mask discomfort, excessive noise, and the cumbersome maintenance required. Additionally, studies show that patients often discontinue use due to a lack of understanding about device operation or how to resolve malfunctions, underscoring the critical role of follow-up care by healthcare providers. (5)
The consequences of abandoning OSA treatment can be severe—and even fatal. Beyond persistent fatigue and diminished quality of life, untreated OSA has been linked to an increased likelihood of heart attacks, strokes, metabolic disorders, and other chronic conditions. These include high blood pressure, glaucoma, diabetes, cancer, fibromyalgia, erectile dysfunction, depression, anxiety, and ADD/ADHD, among others. (6-9)
Even more concerning, recent evidence suggests CPAP therapy may not sufficiently mitigate all of these risks. Three recent randomized clinical trials examining CPAP therapy for the secondary prevention of cardiovascular disease in patients with OSA failed to demonstrate any significant cardiovascular improvements. (1) This highlights a critical issue: by focusing solely on symptom management rather than addressing the root causes of OSA, CPAP therapy leaves patients vulnerable to ongoing health risks.
Although CPAP has historically been the gold standard for OSA treatment, its limitations—including low compliance and lack of comprehensive health benefits—have left many patients seeking better solutions. For a significant number of individuals, the drawbacks of CPAP outweigh its benefits, often leading to treatment discontinuation and the progression of untreated OSA.
"No one wants to hear that they'll spend the rest of their nights connected to a machine," emphasizes Huntsman. "But ignoring OSA is not an option—it doesn't simply go away. That's why we at Vivos believe every patient deserves a treatment that can address and potentially resolve OSA rather than simply managing it for life."
A Breakthrough Solution: The Vivos CARE Oral Medical Devices
Vivos CARE oral medical devices, powered by the proprietary Vivos Method, are revolutionizing the treatment of obstructive sleep apnea (OSA). This noninvasive, nonsurgical approach targets the underdeveloped anatomy of the airway, gradually remodeling the palate and upper jaw to prevent airway collapses during sleep. In about 12 months or less, this groundbreaking therapy helps patients achieve long-lasting results.
In addition to the CARE devices, Vivos offers a comprehensive and multidisciplinary approach to improve sleep health. Patients benefit from seamless access to home sleep tests, diagnoses, and telemedicine consultations with board-certified sleep physicians across all 50 states. This integrated care model ensures accurate diagnoses and personalized treatment plans tailored to each individual.
With its comfort and ease of use, it's no surprise that when newly diagnosed patients are presented with CPAP and the Vivos CARE treatment, 8 out of 10 choose Vivos over CPAP.
What Sets Vivos Apart:
- Shorter Treatment Times: Typical Vivos CARE treatment times are 12 months or less. Individual results can vary.
- Root Cause Resolution: Unlike CPAP, which only manages symptoms, Vivos CARE addresses and corrects the structural issues behind the majority of OSA cases.
- Patient Comfort: Free from the discomfort, noise, and maintenance burdens of CPAP, Vivos CARE encourages better adherence.
- Potentially Lasting Results: In nearly 60,000 patients treated using Vivos CARE devices since 2010, less than 0.1% required full retreatment.
"Vivos is redefining what it means to treat sleep apnea," says Kirk Huntsman, Chairman and CEO of Vivos Therapeutics. "By addressing the condition at its roots, we're not just helping patients achieve quality sleep—we're empowering them to reclaim their overall health and well-being."
About VIVOS THERAPEUTICS
Obstructive sleep apnea (OSA) affects over 1 billion people worldwide, yet 90% remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep issue—it's closely linked to nearly every modern chronic health condition. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, solutions are often mechanistic and fail to address the root causes of OSA.
Vivos Therapeutics, founded in 2016 and based in Littleton, CO, is changing this. Through innovative technology, education, and partnerships with dentists, functional medicine doctors, and sleep specialists, Vivos is empowering healthcare providers to more thoroughly address the complex needs of patients. Their groundbreaking device is the only FDA 510(k) cleared technology for treating severe OSA and the first to receive clearance for treating moderate to severe OSA in children.
The Vivos Method offers a unique, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope for patients with mild to severe OSA. Vivos: Breathe New Life. For more information, visit http://www.vivos.com.
References
1. Peker, Y., Celik, Y., Behboudi, A., Redline, S., Lyu, J., Ying, W., Gottlieb, D. J., and Jelic, S.; "CPAP May Promote an Endothelial Inflammatory Milieu in Sleep Apnea After Coronary Revascularization"; eBiomedicine; Feb. 24, 2024; thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00050-1/fulltext.
2. Benjafield, Adam V, et al. "Estimation of the Global Prevalence and Burden of Obstructive Sleep Apnea: A Literature-Based Analysis." The Lancet Respiratory Medicine, vol. 7, no. 8, Aug. 2019, pp. 687–698, thelancet.com/journals/lanres/article/PIIS2213-2600(19)30198-5/fulltext, doi.org/10.1016/s2213-2600(19)30198-5.
3. Magnusdottir, Solveig, and Elizabeth A. Hill. "Prevalence of Obstructive Sleep Apnea (OSA) among Preschool Aged Children in the General Population: A Systematic Review." Sleep Medicine Reviews, vol. 73, 1 Feb. 2024, p. 101871, sciencedirect.com/science/article/abs/pii/S1087079223001272#:~:text=Studies%20published%20before%202014%20reported, doi.org/10.1016/j.smrv.2023.101871.
4. Qiao, M., Xie, Y., Wolff, A. et al.; "Long-term adherence to continuous positive Airway pressure in mild obstructive sleep apnea"; BMC Pulm Med 23, 320 (2023); doi.org/10.1186/s12890-023-02612-3.
5. Patel SR, Bakker JP, Stitt CJ, Aloia MS, Nouraie SM; "Age and Sex Disparities in Adherence to CPAP"; Chest; 2021 Jan; pmc.ncbi.nlm.nih.gov/articles/PMC7803941/#:~:text=Results,weekends%20compared%20with%20weekday%20nights.
6. Drager, Luciano F., et al. "Sleep Apnea and Cardiovascular Disease." Circulation, vol. 136, no. 19, 7 Nov. 2017, pp. 1840–1850, doi.org/10.1161/circulationaha.117.029400.
7. G JEAN-LOUIS, et al. "Obstructive Sleep Apnea and Cardiovascular Disease: Evidence and Underlying Mechanisms." Minerva Pneumologica, vol. 48, no. 4, Dec. 2009, p. 277, pmc.ncbi.nlm.nih.gov/articles/PMC3106988/.
8. Kazuki Shiina. "Obstructive Sleep Apnea -Related Hypertension: A Review of the Literature and Clinical Management Strategy." Hypertension Research, 29 Aug. 2024, nature.com/articles/s41440-024-01852-y, doi.org/10.1038/s41440-024-01852-y.
9. Romina Abelleira, et al. "Relationship between Obstructive Sleep Apnea and Type 2 Diabetes Mellitus." Medicina Clínica, 1 Apr. 2024, doi.org/10.1016/j.medcle.2023.11.014. Accessed 28 May 2024.
Media Inquiries:
Karla Jo Helms
JOTO PR™
727-777-4629
jotopr.com
Media Contact
Karla Jo Helms, JOTO PR™, 727-777-4629, [email protected], jotopr.com
SOURCE Vivos Therapeutics
Share this article